Literature DB >> 17766633

Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators.

M Christ-Crain1, B Müller.   

Abstract

Used appropriately, biomarkers improve the assessment of respiratory tract infections and sepsis. Most prominently, circulating procalcitonin levels increase by a factor of several tens of thousands during sepsis. Using a sensitive assay, procalcitonin safely and markedly reduces antibiotic usage in respiratory tract infections and nonbacterial meningitis. Procalcitonin is the protopye of hormokine mediators. The term "hormokine" encompasses the cytokine-like behaviour of hormones during inflammation and infections. The concept is based on a ubiquitous expression of calcitonin peptides during sepsis. Adrenomedullin, another member of the calcitonin peptide superfamily, was shown to complement and improve the current prognostic assessment in lower respiratory tract infections. Other peptides share some features of hormokines, e.g. natriuretic peptide and copeptin. Hormokines are not only biomarkers of infection but are also pivotal inflammatory mediators. Like all mediators, their role during systemic infections is basically beneficial, possibly to combat invading microbes. However, at increased levels they can become harmful for their host. Multiple mechanisms of action were proposed. In several animal models the modulation and neutralisation of hormokines during infection was shown to improve survival, and thus might open new treatment options for severe infections, especially of the respiratory tract.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17766633     DOI: 10.1183/09031936.00166106

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  58 in total

Review 1.  Use of plasma procalcitonin levels as an adjunct to clinical microbiology.

Authors:  David N Gilbert
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

2.  Community-acquired pneumonia: 2012 history, mythology, and science.

Authors:  Gerald R Donowitz
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

3.  Determining the Clinical Utility of an Absolute Procalcitonin Value for Predicting a Positive Culture Result.

Authors:  Erica M Caffarini; Joshua DeMott; Gourang Patel; Ishaq Lat
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations.

Authors:  Derek N Bremmer; Briana E DiSilvio; Crystal Hammer; Moeezullah Beg; Swati Vishwanathan; Daniel Speredelozzi; Matthew A Moffa; Kurt Hu; Rasha Abdulmassih; Jina T Makadia; Rikinder Sandhu; Mouhib Naddour; Noreen H Chan-Tompkins; Tamara L Trienski; Courtney Watson; Terrence J Obringer; Jim Kuzyck; Thomas L Walsh
Journal:  J Gen Intern Med       Date:  2018-02-05       Impact factor: 5.128

Review 5.  Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis.

Authors:  H Tang; T Huang; J Jing; H Shen; W Cui
Journal:  Infection       Date:  2009-10-13       Impact factor: 3.553

6.  Modern Management of Community-Acquired Pneumonia: Is It Cost-Effective and are Outcomes Acceptable?

Authors:  Dominik Mertz; Jennie Johnstone
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

7.  Determining the duration of therapy for patients with community-acquired pneumonia.

Authors:  Nikole M Scalera; Thomas M File
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

8.  Mast cell tryptase and carboxypeptidase A expression in body fluid and gastrointestinal tract associated with drug-related fatal anaphylaxis.

Authors:  Xiang-Jie Guo; Ying-Yuan Wang; Hao-Yue Zhang; Qian-Qian Jin; Cai-Rong Gao
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

9.  Procalcitonin Levels in Acute Respiratory Infection.

Authors:  Kelsey M Henriquez; Mary S Hayney; David P Rakel; Bruce Barrett
Journal:  Viral Immunol       Date:  2016-01-07       Impact factor: 2.257

Review 10.  Biomarkers: a definite plus in pneumonia.

Authors:  Hanssa Summah; Jie-Ming Qu
Journal:  Mediators Inflamm       Date:  2009       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.